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ABSTRACT 
 
 
During their life, humans are exposed to numerous substances that are naturally 
present in the environment or that are the result of man made processes, including heavy 
metals, persistent organic pollutants, pesticides and veterinary drugs.  Some of these 
substances can leave residues in food products and possibly expose consumers to their 
potential toxic effects.  To address these problems extensive regulatory efforts are 
devoted to prevent, detect and control these substances from reaching the food supply.  
However, given the vast diversity of food products that requires monitoring and the 
immense diversity of potential chemical contaminants, the need for an efficient and 
vigilant residue prevention program cannot be underestimated.  Residue concentrations in 
animal food products are generally determined in samples collected from edible tissues 
(e.g. muscle, liver, skin, fat) which can lead to a loss of valuable product.  Additionally, 
variations between different edible tissues and products require the development and use 
of specific analytical procedures.  This dissertation presents different aspects related to 
the nature and origin of potential chemical residues in food products and the regulatory 
process used for their prevention and control.  Finally, it discusses the possible use of 
body fluids, namely blood, as a predictive indicator of the concentrations of antibiotic 
residues in target tissues for monitoring purposes.  
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PREFACE 
Antibacterial drugs are among the most frequently used treatments in animal 
production (FDA, 2000; Botsoglou and Fletouris, 2001; Donoghue, 2003).  These drugs 
have a critical role in the promotion of animal health, welfare and productivity.  
Additionally they are important in the prevention of the spread of pathogens from 
animals to humans, either by direct contact to producers or farm workers or indirectly via 
food products (Berkelman, 1994; von Essen and McCurdy, 1998).  Yet, despite the 
benefits provided by these drugs, some of them can leave residues in the edible tissues of 
food producing animals (e.g. muscle, liver, kidney, skin or food products like eggs).  In 
some cases, these residues can predispose consumers to health problems such as allergic 
or toxic reactions, or chronic conditions such as mutagenesis or carcinogenesis (Craigmill 
and Cortright, 2002; Anderson et al., 2003; Donoghue, 2003).   
To protect consumers from potentially harmful concentrations of antibacterial 
residues, the Federal Government conducts extensive procedures to ensure the safe usage 
of these drugs in food producing animals (NRC, 1999; VICH-FDA, 2008; FDA, 2009a; 
21CFR500.84, 2010; 21CFR514, 2010).  During the preapproval process for veterinary 
drugs, studies are conducted to determine safe and efficient protocols for use. This 
process also includes specific studies on the characteristics of drug incorporation in the 
target animal including absorption, distribution, metabolism, storage and excretion 
(Riviere, 1991; Martín-Jiménez and Riviere, 1998).  One of the most important results of 
these studies is the identification of the edible tissue in which the concentration of 
residues persists for the longest period of time at the highest concentration.  This tissue, 
called the target tissue, is then used to monitor the safety of edible tissues from food 
 ix 
producing animals (Clement, 1995).  Federal inspectors collect samples of the indicated 
target tissue to determine concentrations of residues in that edible tissue and then use 
results to estimate the concentration of residues in other tissues in the animal.  Based on 
these determinations, it will be determined if the edible tissues of the animal are safe for 
human consumption. 
Since the monitoring procedure requires collection of edible tissues for analysis 
(e.g. muscle), it can represent a monetary loss for the producer and therefore can limit the 
number of samples collected for each group of animals.  From the inspector’s 
perspective, the collection of samples from edible tissues at the processing plant can be a 
cumbersome process.  Processing lines at poultry slaughter houses can move at speeds of 
approximately 70-160 birds per minute, making sample collection difficult (Berrang et 
al., 2007, 21CFR381, 2010).  Furthermore, due to variations among the different types of 
tissues for monitoring purposes (e.g. muscle, liver, kidney, etc.), analytical procedures 
used to quantitate concentrations of residues must be developed for each specific tissue 
(Marazuela and Bogialli, 2009).   
An alternative strategy to monitor residues in animals would be the use of blood 
as an indicator of the concentration of residues in the target tissue.  This sampling 
strategy would simplify sample collection at the processing plant, reduce costs to 
producers due to product loss and expedite analytical procedures for residue quantitation.  
Few studies have been published examining this strategy to predict residue 
concentrations in edible poultry tissues.  Because of the paucity of literature regarding 
this approach to monitoring, the review of literature will focus on occurrence of antibiotic 
residues in food animals, their significance to human health and the pre-approval and 
 x 
post-approval monitoring process for these residues.  Finally, pharmacokinetic data will 
be presented and discussed in two manuscripts regarding the ability to predict residues 
content in poultry muscle based upon blood concentrations. 
 xi 
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CHAPTER I 
LITERATURE REVIEW 
ANTIBACTERIAL RESIDUES IN ANIMAL FOOD PRODUCTS AND THEIR 
SIGNIFICANCE TO HUMAN HEALTH 
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1. INTRODUCTION 
As the global population exceeds the 6.7 billion mark (U.S. Census Bureau, 
2010), the demand for inexpensive, plentiful, wholesome and safe food products has 
never been greater (Tilman et al., 2002; OECD-FAO, 2009).  Yet, at the same time, most 
consumers are concerned about the methods used for food production and the 
consequences of those agricultural practices on human animal and environmental health 
(Bruhn, 1999; Willis, 2000; Gorback, 2001; Tilman et al., 2002).  One such practice that 
has attracted the public’s attention is the use of veterinary drugs in agricultural settings 
and their potential presence as residues in food products (Bruhn, 1999; NRC, 1999; 
Resurreccion and Galvez, 1999; Willis, 2000; Verbeke et al., 2007).  Results from a 
survey conducted in the U.S. by Nicholls and co-workers (1994) indicated that many 
consumers erroneously believe that exposure to chemicals in foods is one of the leading 
causes of death.  Similarly, in the fall of 2005, the Eurobarometer survey showed that 
European consumers rank presence of chemicals, pesticides and toxic substances in food 
second after food poisoning as their main food related concerns (Becker, 2000; European 
Commission, 2006).   
Unfortunately, the perception of risk that most consumers have about chemicals in 
foods is obscured by the lack of differentiation between broad categories of risks.  
Namely, consumers do not discriminate between various types of potential toxicants and 
thus they may perceive compounds like dioxins (organic compounds with very high 
toxicity) and residues of veterinary drugs (with low toxicity) as equally dangerous.  
Numerous authors have also reported that consumers may feel pessimistic about food 
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safety due to lack of confidence in the stringency of the safety and monitoring standards 
and protocols (Lofstedt, 2006; De Jonge et al., 2008, Cope et al., 2010).   
 
2. USE OF ANTIBACTERIAL DRUGS IN FOOD PRODUCING ANIMALS AND 
THEIR RELEVANCE AS POTENTIAL SOURCES OF RESIDUES IN ANIMAL 
FOOD PRODUCTS 
During the production cycle, food producing animals may be dosed with a variety 
of veterinary drugs (NRC, 1999; Botsoglou and Fletouris, 2001).  These compounds are 
used to promote the health, welfare and productivity of food producing animals, reduce 
production costs and retail costs for the consumer (CAST, 1981; Langlois et al., 1986, 
Walton, 1986; Botsoglou and Fletouris, 2001; Donoghue, 2003).  They are also important 
to reduce transmission of pathogenic agents from animals to humans (Berkelman, 1994; 
Von Essen and McCurdy, 1998).   
Unfortunately, some antibacterial drugs and their metabolites may deposit in 
edible tissues which can be detrimental to consumers (Paige et al., 1997; Cerniglia and 
Kotarski, 1999; Donoghue, 2003).  Antibacterial residues are characterized as 
pharmacologically active substances, whether active principles, excipients or degradation 
products and their metabolite(s) that persist in foodstuffs obtained from plants or animals 
that have been exposed to an antibacterial (Botsoglou and Fletouris, 2001; McGlinchey et 
al., 2008).  Most of these residues are limited to specific tissues and tend to be stored and 
maintained for a short time and are innocuous to the host (VICH-FDA, 2010a).  
However, when present in edible tissues, consumers can be unknowingly exposed to 
these antibacterial residues.  This is of particular importance in the case of antibacterials 
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that can induce health problems in consumers such as allergic or toxic reactions, or 
predispose to teratogenesis, carcinogenesis or mutagenesis (Craigmill and Cortright, 
2002; Anderson et al., 2003; Donoghue, 2003).  Thus it is important that producers, 
veterinarians and all involved in food production are aware and follow the approved 
labeling instructions for drugs used in animals to protect consumers from potentially 
harmful concentrations of residues in food products (Anadon and Martinez-Larrañaga, 
1999; Willis, 2000). 
 
2.1 ANTIBACTERIAL DRUGS 
Antibacterials are defined as compounds that are capable, at low concentrations, 
of killing or inhibiting the growth of microorganisms (Botsoglou and Fletouris, 2001; 
Walsh, 2003).  The term antibacterial includes two general classes of these drugs: 
antibiotics which are of natural origin and antibacterials which are synthetic or semi-
synthetic compounds (Hagren et al., 2005; Marazuela and Boglialli, 2009).  In general, 
the types of antibacterial drugs used for the control, prevention and treatment of diseases 
in animals are similar to those used to treat humans (Crosby, 1991; Prescott, 2008).   
Antibacterials have been used in agriculture since the 1940s to improve animal 
wellbeing and production (Jones and Ricke, 2003).  Currently, there are over 7,000 
identified antibacterials and several hundred specific antibacterial applications are 
approved for use in the U.S. for animal production.  It is estimated that a large proportion 
of the livestock and poultry in the U.S. and in the world, receive antibacterials regularly 
during their production cycle (FDA, 2000; Botsoglou and Fletouris, 2001; Donoghue, 
2003).  In the U.S. the Animal Health Institute estimated that annually over 8,000 metric 
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tons of these compounds are used in the production of the three major food producing 
animal species (swine, cattle and poultry), whereas the Union of Concerned Scientists 
estimated that quantity at over 11,000 metric tons per year (Mellon et al., 2001).  In other 
parts of the world the use of antibacterials remains relatively unregulated and 
undocumented, therefore comprehensive reports on the quantity and type of antibacterials 
used for agricultural purposes in the world are unavailable (Katz and Ward, 2004).   
 
a. Sulfonamides (e.g. sulfamethazine, sulfamethiozole, sulfadiazine, sulfamerzine, 
sulfanilamide, sulfadimethoxine, sulfapyridine and sulfaquinoxaline) are widely used in 
animal husbandry, for prophylactic and therapeutic purposes, particularly for respiratory 
conditions (Wang et al., 2006).  Unfortunately, exposure to sulfonamides can induce 
adverse reactions in people including photosensitivity, thyroid toxicity (particularly 
caused by sulfadimidine), toxic epidermal necrolysis (Stevens-Johnson Syndrome and the 
severe form of the disease called Lyell Syndrome), urinary tract disorders, porphyria, 
hematopoietic disorders, onset of fetal hyperbilirubinemia and kernicterus during late 
pregnancy, as well as teratogenic effects (Dunn, 1964; Swarm et al., 1973; Peters et al., 
1990; Mitchel, 1994; NRC, 1999; Slatore and Tilles, 2004; Wang et al., 2006).  It has 
been reported that sulfonamides can induce hypersensitivity reactions in approximately 
10% of the general population and about 60% of patients with human immunodeficiency 
virus (HIV; Dewdey et al., 1991; Dayan, 1993; Berends et al., 2001).   
Sulfonamides have a number of characteristics that increase their potential for 
leaving residues in treated animals.  For example, these drugs tend to be eliminated 
unchanged from the body and be disseminated to untreated animals through feed, water 
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or environmental contamination.  Furthermore, as these drugs tend to persist for long 
periods of time in the environment this can lead to an underestimation of the exposure 
risk (Bevill, 1984, 1989; Van Dresser and Wilcke, 1989; McCaughey et al., 1990; 
Waltner-Toews and McEwen, 1994a, 1994b; Riviere and Spoo, 2001; Buur et al., 2006; 
Agwuth and MacGowan, 2006).  Sulfonamides can also persist at injection sites for over 
30 days after application, in contrast to other antibacterials that disappear from the 
injection site within 24 hours such as neomycin, tylosin and oxytetracycline (Galer and 
Monro, 1996; Van Donkersgoed et al., 1999; Reeves, 2005, 2007).   
 
b. Penicillins, include antibacterials such as benzypenicillin (also called penicillin G), 
ampicillin, amoxicillin, cloxacillin, cephapirin, and ceftiofur (21CFR556, 2010).  These 
antibacterials are classified as members of the group of the β-lactams.  These 
antibacterials have been used widely in both human and veterinary medicine for over half 
a century (Wright, 1999).  These compounds and their numerous metabolites can induce 
allergic reactions in several mammalian species.  As a result, penicillins may elicit a 
variety of allergic reactions ranging from mild skin rashes to potentially fatal anaphylaxis 
(Adcock and Rodman, 1996; Jiminez et al., 1997).  It has been estimated that 
approximately 10% of the population are allergic to these antibacterials, and that 
exposure to penicillins may account for up to 75% of deaths due to drug anaphylaxis in 
the United States (mainly caused by exposure during medical treatments; Idsoe et al., 
1968; Delage and Irey, 1972). 
Although there is a significant percentage of the population allergic to these 
compounds, it is very difficult to quantify the public health risk by β-lactam residues in 
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foods (Dewdney and Edwards, 1984).  There are few identifiable cases of allergic 
reactions to penicillin caused by antibacterial residues in food.  One report from 1984 
indicated that a patient had developed pruritis, difficulty in swallowing and speaking 
within 20 minutes of eating a steak dinner.  The meat was later found to contain penicillin 
(Schwartz and Sher, 1984).  Another similar incident was reported after pork 
consumption (Tscheuschner, 1972).  There has even been a report of anaphylaxis after 
the consumption of a β-lactam adulterated soft drink (how this occurred could not be 
determined; Wicher and Reisman, 1980).  Interestingly, Lindemayr and co-workers 
(1981) reported that when penicillin allergic volunteers ate meat containing penicillin 
residues only a very small fraction of them developed allergic symptoms.  The results of 
this experiment and the scarcity of verifiable incidents of adverse reactions to penicillin 
residues in foods suggest that allergic reactions caused by β-lactam residues in foods may 
be rare (Dewdney et al., 1991; Woodward, 1991; Dayan, 1993; McEwen and McNab, 
1997; Woodward, 2005). 
Similar to the sulfonamides, most β-lactams are excreted unchanged and thus can 
cause unintentional exposure to untreated animals.  In the case of β-lactams that are 
metabolized before excretion, they retain their allergenic potential and thus still pose a 
danger for consumers (Assem and Vickers, 1974, 1975; Basomba et al., 1978; 
Pirmohamed et al., 1994; Gerber and Pichler, 2006; Roujeau, 2006).  Some β-lactam 
metabolites have prolonged half lives.  For example, amoxicilloic acid is one of the most 
allergenic metabolites of the antibacterial amoxicillin and has a longer half life then the 
parent compound (Reyns et al., 2008).  Thus monitoring of these metabolites needs to be 
considered during the residue monitoring process. 
 8
 
c. Cephalosporins (e.g., cefalonium, cefalexin, ceftiofur, cefazolin, cefacetril) are an 
important class of antibacterial agents used for both human and animal medicine.  To 
date, scientists have developed four generations of cephalosporins, all of which share the 
same β-lactam sub-structure first found in penicillin.  With regards to animal production, 
most first and second generation cephalosporins are commonly used worldwide for the 
treatment of mastitis infections in dairy cattle, while the third and fourth generations of 
cephalosporins are primarily used for other veterinary purposes (Hornish and Kotarski, 
2002).  As such, these antibacterials are a common source of residues in milk and dairy 
products.  This is a concern for both human health and also the manufacture of dairy 
products, such as cheese due to possible interference of the antibacterials with the 
microorganisms used to make them (Molina et al., 2003).  Several on-farm residue 
screening tests are available to monitor treated cows to prevent residues from entering the 
food supply (Jones and Seymour, 1988; Kang et al., 2005).   
Health concerns associated with these antibacterials are related to their allergenic 
potential, as about 5% of the general population appears to be allergic to these 
compounds (Botsoglou and Fletouris, 2001).  Also, several cephalosporins, particularly, 
those classified as third generation (such as ceftiofur, cefixime, cefdinir and cefotaxime), 
can cause renal damage through hypersensitivity-induced interstitial nephritis or through 
direct toxicity of the renal tubules and thus represent a source of concern for already 
renally compromised patients (Fekety, 1990; Schliamser et al., 1991).  Finally, these 
antibacterials have recently been associated with the apparent development of 
cephalosporin resistant pathogenic bacterial strains, consequently the extralabel use of 
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these antibacterials has been banned (FDA, 2008). 
 
d. Tetracyclines (e.g., tetracycline, doxicycline, chlortetracycline and oxytetracycline) 
represent about half of all antibacterials used in animal production due to their low cost 
and are consequently one of the most commonly detected antibacterials in foods (Lynas 
et al., 1998; Kennedy et al., 2000; Oka et al., 2000; Guigere, 2006).   
The tetracyclines are known for their ability to cause acute allergic reactions and 
thus are a major concern as residues in food products (Botsoglou and Fletouris, 2001).  
Also, it has been reported that some tetracycline residues can undergo heat degradation 
during cooking processes and produce toxic metabolites, which may have nephrotoxic 
properties (Fedeniuk, 1988; Rose et al., 1996; Moats, 1999).  Tetracyclines are rapidly 
eliminated from edible tissues, thus in most cases a withdrawal period of only 24 hours is 
generally enough for concentrations to fall below the tolerance level (McEvoy et al., 
1994; Lynas et al., 1998).  In bone tissue, however, most tetracyclines bind almost 
irreversibly (Korner et al., 2001; Zakeri and Wright, 2008) and bonemeal used from 
treated animals can result in an unintentional source of residues in the animals. 
 
e. Chloramphenicol has been included in the list of prohibited drugs for food producing 
animals because it may cause several health problems in consumers including cyanosis, 
respiratory failure (including the grey baby syndrome in newborns) and aplastic anemia 
(FDA, 1996; Kasten, 1999; Johnson, 2003; Hagren et al., 2005).  Aplastic anemia is fatal 
in about 70% of cases and for those that survive; there is a sharp increase in the 
probability of developing leukemia (Fraunfelder, 1982; Fraunfelder et al., 1982; 
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Settepani, 1984; Page, 1991; NRC, 1999; Botsoglou and Fletouris, 2001).  This disease 
appears in approximately 1:10,000 to 1:45,000 humans who receive chloramphenicol 
(Papich and Riviere, 2001). 
An important characteristic of chloramphenicol’s toxic effects is that they are not 
dose dependent, but rather related to the sensitivity of the individual (Hagren et al., 
2005).  Therefore, even low concentrations of this antibacterial via systemic (such as 
from food) or in topical exposure can cause toxic effects.  Because there is no safe 
concentration for this drug, chloramphenicol is banned from all use in food animals 
(Black 1984; Settepani, 1984; Norcross and Post, 1990; Page, 1991; Cooper et al., 1998; 
NRC, 1999; Codex Committee, 2004; 21CFR530, 2010).  
Because of these risks, surveillance for this compound in U.S. and imported food 
products is a high priority for regulatory agencies.  Imported foods are a particular 
concern since chloramphenicol is used in many countries (e.g., widely used in China).  
Legal prosecution is vigorously pursued for violators, in accordance with 
21U.S.C.331(a), through the FDA’s Office of Criminal Investigations (Norcross and 
Post, 1990; Norcross and Brown, 1991; Botsoglou and Fletouris, 2001; FDA, 2002a).  It 
is also important to mention that chloramphenicol is an antibiotic naturally produced by 
soil organisms of the genera Streptomyces and thus animals may unintentionally be 
exposed to small amounts of this compound (Wongtavatchai et al, 2005)  
 
f. Nitrofurans and nitroimidazoles  deserve special attention because they are 
carcinogenic (FDA, 2009b) and have been banned for use in the U.S. since the early 
1990s and banned for extra-label use since 2002 (FDA, 2002b).  In addition to being 
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carcinogenic some people may be hypersensitive to this product and liver damage during 
pregnancy and a syndrome similar to autoimmune hepatitis have been described (De 
Groot and Conemans, 1990; Peedikayil et al., 2006; Aksamija et al., 2009).  These 
antibacterials form stable and irreversible deposits in the animals and thus, the use of 
these drugs in even young animals can cause residues at slaughter.  Studies have shown 
that even topical (ocular) applications of nitrofurans may result in residues in the tissues 
and organs of the animals, including milk (FDA, 2002b).   
Due to their potential toxic effects, the nitroimidazoles have been banned for use 
in production animals in both the U.S. and the European Union.  Unfortunately, as in the 
case of chloramphenicol, these compounds are still used in other countries such as 
Burma, Thailand, Vietnam and China and are a significant source of contamination in 
shellfish and fish products imported from those countries (Hagren et al., 2005; FDA, 
2009a).   
 
g. Aminoglycosides (streptomycin, neomycin, gentamicin, lincomycin, bambermycin) 
are generally known for their ototoxic and nephrotoxic properties in both animals and 
humans (Drusano et al., 2007).  Damage to the ear, primarily the vestibular and cochlear 
nuclei, has been particularly noted in the case of children exposed to these compounds 
during pregnancy (Al-Aloul et al., 2004; Matz et al., 2004; Selimoglu, 2007).  The 
incidences of mild to severe renal effects in patients treated with these antibacterials have 
been reported at around 10-25% (Taber and Pasko, 2008).  Additionally, allergic 
reactions associated to these compounds have been reported (Tinkelman and Bock, 1984; 
Faridah et al., 2004).  The Federal government has imposed very low tolerance levels and 
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long withdrawal periods for these compounds in food products, particularly for 
neomycin, because these compounds tend to remain in the ear and kidneys for prolonged 
periods of time, sometimes months, after treatment (Stead, 2000; Gehring et al., 2005).  
 
h. Quinolones or fluoroquinolones (oxolinic acid, nalidixic acid, flumequine, 
enrofloxacin, sarafloxacin, danofloxacin, orbifloxacin, marbofloxacin, gatofloxacin, 
grepafloxacin) have been widely used in animal production.  These compounds are 
associated with potential damage to articular cartilages and tendons (particularly in 
children), as well as myalgia (Eisele et al., 2009) and neurological disorders (depression, 
confusion, anxiety; Takizawa et al., 1999a, 1999b; Ambrose et al., 2007; Kiangkitiwan et 
al., 2008).  Some of these antibacterials, such as enrofloxacin, danofloxacin and 
orbifloxacin, have been prohibited from any use in food animals due to their possible role 
in the development of bacterial resistance (FDA, 2005a).  Concerns regarding resistance 
associated with fluoroquinolone use in animal production were first expressed by Elam 
and co-workers (1951) and are an important factor in the regulation of these compounds 
(Swann Report, 1969; Piddock, 1996; NRC, 1999; Tollefson and Flynn, 2002; Angulo et 
al., 2004; Grugel and Wallmann, 2004; Turnidge, 2004; FDA, 2010; Sharfstein, 2010). 
 
3. REGULATION OF VETERINARY DRUGS AS POTENTIAL SOURCES OF 
RESIDUES IN ANIMAL FOOD PRODUCTS  
The federal regulatory oversight of the safety of veterinary drugs can be divided 
into two different stages: the premarket approval determination which establishes if a 
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drug is safe for use and the post-approval monitoring to ensure drugs are used correctly 
and to test food samples for violative residues (Botsoglou and Fletouris, 2001).  
 
3.1. Pre-approval regulatory process regarding veterinary drug residues in animal 
food products 
The premarket process is the responsibility of the Food and Drug Administration 
(FDA) through the Center for Veterinary Medicine (CVM).  The approval process starts 
when the sponsor submits an investigational veterinary pharmaceutical product (IVPP) 
application to the Office of New Animal Drug Evaluation (ONADE) at the FDA-CVM, 
in accordance with the Title 21 of the Code of Federal Regulations (CFR), Parts 500 to 
599.  These CFR sections govern animal drugs, animal feeds and associated products; as 
well as specific regulations on registration, labeling and good manufacturing and 
laboratory practices (also included in Parts 200 to 299).  Additionally, recent efforts for 
international harmonization of regulatory requirements for veterinary medical products 
have been published by the International Cooperation of Technical Requirements of 
Veterinary Medicinal Products (VICH) of the World Organization for Animal Health 
(OIE) and adopted by its members, including the U.S. and the European Union. 
The FDA-CVM requires that the sponsor of all potential new veterinary 
pharmaceutical products conduct research in five main areas: 1) drug’s efficacy, 2) safety 
of the drug for the target animal, 3) safety for the consumers of food products derived 
from those animals, 4) environmental impact and 5) quality of the manufacturing 
processes (NRC, 1999; VICH-FDA, 2008; FDA, 2009a; 21CFR514, 2010; 
21CFR500.84, 2010).   
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As part of the evaluations on the food safety of products derived from medicated 
animals, the sponsor must consider the known pharmacologic and toxicologic properties 
of the active pharmaceutical ingredient (API), as well as conduct experiments to 
determine the acute and chronic toxic potential of the drug for each proposed application, 
(VICH-FDA, 2008; 21CFR500, 2010).  Experimental animals are administered various 
doses of the compound to detect any toxic effects, such as the allergenic, carcinogenic, 
teratogenic or mutagenic properties of the drug (VICH-FDA, 2008).  An important goal 
of these studies is to determine the dosing level that causes no harmful effects (Fink-
Gremmels and van Miert, 1994; Donoghue 2003; Hurtt et al., 2003; FDA, 2009a).  This 
level is called the no-observable adverse effect level (NOAEL or NOEL) and is used to 
establish a tolerance level for residues in edible tissues (Craigmill and Cortright, 2002).  
The tolerance level is established by taking the antibacterial dose at the NOAEL, 
reducing this dose by 100- or 1,000-fold (safety factor) and multiplying by the average 
daily intake of the edible tissue (e.g., poultry muscle) for a 60-kg adult.  A safety factor 
of 100 is usually applied for antibacterials already in use (e.g., other animals, humans) 
with a known safety record.  Otherwise, a safety factor of 1,000 is used (Donoghue, 
2003). 
The tolerance level is defined as the safe concentration of residues that are 
permitted in human food products (NRC, 1999; Paige et al., 1999b; Botsoglou and 
Fletouris, 2001; 21CFR530 and 556, 2010).  Tolerance levels are determined for each 
individual edible product and are specific for each drug and animal species (Clement, 
1995; Paige et al., 1999b; Botsoglou and Fletouris, 2001; 21CFR500.86, 2010; 
21CFR556, 2010).  If a tolerance level cannot be imposed on a drug due to potential toxic 
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effects to consumers, the antibacterial will be banned from use in food producing animals 
and any use would be considered illegal, as is the case with chloramphenicol (Hanekamp 
and Kwakman, 2004).  Once the tolerance level has been determined, the FDA-CVM will 
provide the appropriate dosage protocols for the drug, and specific sampling procedures 
for monitoring of residues in these animals (21CFR514, 2010).  This information must be 
included on the label of the product, or any written, printed or graphic material 
accompanying the product (21CFR514, 2010).   
Studies are also conducted to evaluate the patterns of absorption, distribution, 
biotransformation and excretion of the drug, as well as the amounts, persistence and 
nature (parent drug and/or metabolites) of any drug derived residue in the edible tissues 
of the treated animal (Riviere, 1991; Martín-Jiménez and Riviere, 1998).  The results of 
these studies and those from the total residue depletion study and metabolism studies are 
used to identify possible reservoir sites and determine the time required for the depletion 
of all drug related residues from the animal and its edible tissues (Clement, 1995; CVM, 
2006; 21CFR500.86, 2010).  
Based on the results of these safety studies, the FDA will impose and publish the 
conditions for drug usage for each approved animal species.  If approved drugs are used 
properly and in compliance with label directions, there should be no violative residues 
(those that exceed the tolerance) in edible food products from treated animals.  In several 
countries, the regulatory agencies have established tolerance limits for acceptable daily 
intake (ADI) and tolerance limits (also called maximal residue limits or MRLs in the 
European Union) for the amount of the drug and/or its metabolites that might be present 
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in animal products.  Nonetheless, residues exceeding tolerances do occur requiring 
monitoring to detect and take remedial action to prevent its reoccurrence.   
 
3.2 Post approval monitoring process for veterinary drug residues in animal food 
products 
The government agencies primarily responsible for post approval monitoring of 
drug residues in food products are the USDA though the Food Safety and Inspection 
Service (USDA-FSIS) and the FDA.  The USDA-FSIS is responsible for monitoring 
meat and poultry in federally inspected establishments, as well as and liquid eggs 
whereas the FDA monitors residue levels in milk and shell eggs (FDA, 1997; FDA, 2003; 
Botsoglou and Fletouris, 2000; FSIS, 2007).  FSIS reports violative residues of drugs and 
both violative and non-violative residue levels of pesticides, veterinary drugs and other 
contaminants to the FDA (FDA, 2005b, 2005d). Since the late 1960s, the USDA-FSIS 
has administered the National Residue Program to collect data on chemical residues in 
domestic and imported meat, poultry and egg products.  This program is designed to 
provide: 1) a structured process for identifying and evaluating compounds of concern by 
production class (including approved and unapproved compounds); 2) capability to 
analyze for compounds of concern; 3) appropriate regulatory follow-up of reports of 
violative tissue residues and 4) collection, statistical analysis and reporting of the results 
of these activities (FSIS-NRP, 2008).  
Monitoring procedures are designed to detect and prevent potentially harmful 
concentrations of residues entering the food supply.  The two federal agencies primarily 
responsible for monitoring veterinary drug residue in foods are the FDA and USDA.  
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These sister agencies cooperate to monitor and detect violative residues (concentrations 
of residues that exceed the imposed tolerance levels) or illegal residues (residues of drugs 
specifically prohibited from animal use; Craigmill and Cortright, 2002; Fajt, 2003).  A 
current listing of drugs prohibited for use in animals is codified in 21CFR530 (2010)   
The most obvious reason for the presence of violative residues is a failure to 
observe the recommended withdrawal period for the specific drug.  This may be 
deliberate or accidental.  In the first instance, farmers may deliberately send sick animals 
to slaughter to avoid condemnation of the carcass and monetary loss for the producer 
(Courtheyn et al., 2002; Morley et al., 2005).  Furthermore, as the sampling procedure for 
drug residue testing is often nationwide and quite random, the chances of catching such 
deliberate acts are slim.  This limited sampling can lead to a continuation of such 
practices by farmers.  Farmers can also mistakenly give medicated feed to animals that 
should be on non-medicated feed.  Thus, monitoring of residues in foods provides 
information on failure to follow good animal husbandry practices, misuse of drugs in 
medicated animal feeds, marketing of treated/medicated animals intended for rendering 
purposes, and inadequate animal identification and/or record keeping (Jones and 
Seymour, 1988).  It can also indicate illegal sale of veterinary drugs, incorrect extra-label 
use (which includes inadequate pre-slaughter withdrawal period), cross-contamination of 
animal feeds at the feed mill or drug production errors due to incorrect implementation of 
Good Manufacturing Practices (GMPs; Brynes and Weber, 1996; 21CFR225 and 226, 
2010). 
Scheduled sampling plans consist of the random sampling of tissue from healthy 
appearing food animals in accordance to the available intelligence reports on the 
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prevalence and incidence of specific compounds in food products in a specific location 
(FSIS-NRP, 2008).  These sampling plans are devised with the cooperation of members 
of the NRP-Surveillance Advisory team, that includes members from the Environmental 
Protection Agency (EPA), the Food and Drug Administration (FDA), the Center for 
Disease Control and Prevention (CDC), the Animal and Plant Health Inspection Service 
(APHIS), the Agricultural Marketing Service (AMS), the Agricultural Research Service 
(ARS) and members from the FSIS.  Based on the recommendations of this committee, 
the NRP 1) proposes analytical procedures for identifying and evaluating drugs of 
concern by production class; 2) prioritizes drugs for monitoring; and 3) develops reports 
on the incidence of residue violations (FDA, 2005b). 
In-plant generated sampling occurs when the public health veterinarian suspects 
that an animal or flock may have been treated with a pharmacologically active compound 
which might create residues.  This decision to select and test a specific carcass is based 
on professional judgment and criteria outlined in FSIS Directives 10,800.1 and 10,220.3 
(FSIS, 2007).  These criteria may include animal disease signs and symptoms, producer 
history or results from random scheduled sampling.  When an inspector generated sample 
is collected, the carcass is held pending the results of laboratory testing.  If a carcass is 
found to contain levels of residues that exceed the imposed tolerance level for that 
product in that specific food product, the carcass is condemned (FSIS-NRP, 2008).  In 
addition to being condemned, producer may be subject of legal sanctions (Dey et al., 
2003).  An open record of all notifications and incidents is posted on the websites of 
USDA-FSIS and the FDA and sent to the Residue Violation Information System (RVIS), 
the Microbiological and Residue Computer Information System (MARCIS) and the 
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Tissue Residue Information Management System (TRIMS).  These systems facilitate the 
regulatory follow-up on violations and tracking of residue violators by both FSIS and 
FDA.  Once violative residues are detected, the FDA will conduct an official inquiry, 
financed by the offending producer, which can lead to legal actions that range from 
monetary fines to criminal prosecution, if evidence of prior violations or intent can be 
documented (Guest and Paige, 1991; NRC, 1999; FDA, 2000; Botsoglou and Fletouris, 
2001; FDA, 2005b; FSIS-NRP, 2008).  A detailed description of these procedures can be 
found in the FDA’s guidance document 7371.006 (FDA, 2005c).  
An important aspect of residue monitoring is the development of analytical 
methods for specific drugs and their target tissues (e.g., Schneider and Donoghue, 2000; 
Chu et al., 2000; Heller et al., 2002; Schneider and Donoghue, 2002; Donoghue and 
Schneider, 2003; Schneider and Donoghue, 2004; Reyes-Herrera et al., 2005; Schneider 
et al., 2007; Reyes-Herrera and Donoghue, 2008).  As part of the pre-market approval 
process, the sponsor has to develop a method to evaluate quantitatively and qualitatively 
the relationship between the parent drug and its metabolites in the target tissue in 
accordance to the guidelines for the approval of methods for analysis for residues 
(Clement, 1995; Donoghue, 2003; 21CFR500.86, 2010; VICH-FDA, 2010b).  This 
method is known as the official analytical method and usually consists of surveillance 
and a confirmatory method.  This method is published in the Code of Federal Regulations 
(Engel, 1994; NRC, 1999; 21CFR180, 2010; 21CFR556, 2010).  A list of the official 
methods for the determination and confirmation of the specific drug residues are also 
included in the annual publications from the NRP and in the USDA-FSIS Chemistry 
Laboratory Guidebook (FSIS, 2008).  
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4. MONITORING OF RESIDUES IN FOOD PRODUCTS  
After considering the vast diversity of chemicals that could possibly contaminate 
food products and their numerous potential consequences on the health of consumers, the 
magnitude, difficulties and importance of an efficient and vigilant residue prevention 
program are obvious.  In the 2008 USDA-FSIS National Residue Program Scheduled 
Sampling Plans (Blue Book) there were 22 different types of production classes 
considered including different types of bovine, sheep and goat, swine and poultry, 
products.  The Blue Book lists the veterinary drugs to be monitored and the number of 
samples to be collected from each class during the year.  In brief, this program included 
approximately 23,000 samples in the domestic sampling plan, about 5,000 samples in the 
import sampling plan for a total of roughly 28,000 samples a year.  This is in addition to 
samples collected from suspicious carcasses by the inspectors at the slaughterhouses and 
processing plants (FSIS-NRP, 2008).  Similarly, the report of the FDA-Residue 
Monitoring Program for the fiscal years 2004-2006 included over 7,000 samples 
collected from food products such as grains and grain products, milk and dairy products, 
eggs, fish, shellfish and other aquatic products, fruits, vegetables, nuts and edible seeds, 
water, snack foods, as well as the feed used for food production animals.  All of these 
tests are conducted in the raw ingredients and as part of the Total Diet Study (FDA-TDS, 
2008, 2009).   
It is important to consider that in most cases the complexity of the food matrices 
and the different physico-chemical characteristics of each possible contaminant make it 
difficult for the development of analytical methods appropriate for a great variety of 
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contaminant/food type combinations (Marazuela and Bogialli, 2009).  Accordingly 
analytical procedures need to be developed or modified for the specific type of 
contaminant and food matrix to be analyzed.  Additionally, to improve validation of 
analytical methods for most contaminants in foodstuffs there is a need for the 
development of certified reference materials and matrix blank materials for each of the 
different types of food matrices (Zeleny et al., 2006).  As analytical methods have 
become more sensitive and accurate, sample preparation plays a more critical role in the 
analytical process.  It has been estimated that approximately 50-70% of the time spent on 
residue analysis is used for sample preparation and this also accounts for a large part of 
the cost of analysis (Buldini et al., 2002; Hagren et al., 2005).  For example, complex 
food sample matrices such as muscle also contains connective tissue, nerves and fat that 
needs to be homogenized before any analysis can be conducted.  If the residues (usually 
composed of parent compound and metabolites) are present in a free form they can 
generally be separated from the homogenized food matrix with simple aqueous buffers or 
solvents, but if conjugated or bound residues are formed, then the additional use of 
solvents, proteolysis or hydrolysis steps may be required for accurate determination (such 
as is the case with nitrofurans and florfenicol; Kinsella et al., 2009).  In some cases, the 
food matrices may possess intrinsic substances that interfere with detection of the 
compound, as it can occur with muscle and liver (McGlinchey et al., 2008). These 
difficulties must be considered for residue analysis.   
In contrast to the difficulties of measuring residues in organs and tissues, most 
compounds can be easily quantitated from body fluids (blood, plasma, serum, urine, 
exudates) and only a simple dilution step may be required before analysis (Bacigalupo et 
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al., 1995; Elliot et al., 1996; Hagren et al., 2005).  In humans, plasma, saliva or urine 
samples are used to monitor drug concentrations in therapeutic treatment or to determine 
drug abuse.  This sampling strategy has been used for many years and is widely accepted 
as evidence of drug exposure and to estimate concentrations in the body (Dickson et al., 
1994; Rivier, 2000; Hammet-Stabler et al., 2002; Kim et al., 2002; Rigamonti et al. 
2005).  For animals, several researchers have proposed the use of body fluids as 
predictive indicators of the concentration of residues in target tissues that are intrinsically 
more difficult to analyze (Ashworth et al., 1986; Crooks et al., 1998a, b; Peippo et al., 
2005; Chiesa et al., 2006a; 2006b; Heller et al., 2006; Haasnoot et al., 2007; Schneider et 
al., 2007; 2009; Schneider and Lehotay, 2008).  However, the number of studies in this 
area are limited.   
A couple of studies on the disposition of sulfonamides in sheep identified 
similarities in the pharmacokinetic patterns of these antibacterials in different tissues and 
body fluids (Bevill et al., 1977a; 1977b).  Subsequently, Ashworth and colleagues (1986) 
evaluated the use of blood samples as a means for pig producers to detect animals with 
possible violative or illegal residue concentrations of sulfamethazine before shipping the 
animals for slaughter.  They reported that the concentration of residues in liver (the target 
tissue) would exceed the tolerance limit when concentration in blood exceeded the 45 
ppb (Ashworth et al., 1986).  In cattle, different studies explored the use of blood as a 
predictor of the concentration of antibacterial residues as a preslaughter test (Chiesa et 
al., 2006a; 2006b).  In these studies, the researchers also measured concentration of 
residues in urine and reported that this measurement was highly variable depending on 
factors such as the time stored in the bladder and pH of the urine (Chiesa et al., 2006b). 
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In poultry only one study has examined the blood: tissue relationship of 
antibacterial residues.  Haasnoot and co-workers (2007) evaluated the use of body fluids 
as markers for presence of different sulfonamides in different edible tissues (skin and fat, 
liver, muscle) of broiler chickens.  These researchers reported that the blood: tissue ratio 
varied significantly depending on the tissue, with higher concentrations in blood and 
blood: tissue ratios of 6.2:1 in muscle.  In an effort to evaluate the utility of using blood 
to monitor for residues in muscle, we conducted studies to determine the pharmacokinetic 
relationship between blood and muscle for two different antibacterials (enrofloxacin and 
oxytetracycline) in market aged broiler chickens.    
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ABSTRACT 
 
In 2005, the United States Food and Drug Administration withdrew approval for use of 
enrofloxacin in poultry, thus effectively imposing a zero tolerance for residues of this 
antibiotic in poultry.  Conventional residue monitoring for most antibiotics, including 
enrofloxacin, involves removing poultry carcasses from the processing line and collecting 
muscle tissues for analysis.  Because of the loss of valuable edible products and 
difficulties and expense in sampling all the carcasses, only a small portion of carcasses 
are tested for violative residues.  Unlike muscle tissue, blood is readily available from all 
birds at the beginning of processing and may be used to screen for illegal residues in all 
poultry carcasses.  It is unknown, however, if enrofloxacin concentrations in blood are 
predictive of muscle concentrations.  In an effort to evaluate this relationship, 156 broiler 
chickens, 5 weeks of age, were dosed with either 25 or 50 µg mL-1 enrofloxacin for 3 or 7 
days, respectively, in the drinking water.  Blood and muscle samples were collected at 0, 
1, 3, 6, 12, 24 hours (n=6 birds/group) during the first dosing day, every 48 hours during 
the dosing period, and every 12 hours during withdrawal period for up to 60 hours post 
withdrawal.  Enrofloxacin residues were determined in all blood and tissue samples 
during the dosing periods and most of the withdrawal period for both doses.  These 
results support the potential to use blood to screen for illegal enrofloxacin residues in 
edible poultry tissues in an effort to protect the human food supply.   
 
Key words: Antibiotic residues, Monitoring, Enrofloxacin, Blood: tissue ratio, Broiler  
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INTRODUCTION 
Enrofloxacin is a fluoroquinolone class antibiotic that was developed and used 
exclusively in veterinary medicine.  The United States Food and Drug Administration 
(FDA) approved different specific applications of this drug in 1996, including its use to 
treat bacterial infections in poultry (Anderson et al., 2003).  In 2005, however, the FDA 
withdrew its approval for any use in avian species (including extra-label use; FDA, 2009; 
21CFR530.41, 2010) due to information that linked the use of fluoroquinolones to the 
development of antibiotic resistant strains of Campylobacter, an important human food 
borne pathogen (Anderson et al., 2003; FDA, 2005; Gemer-Smidt and Whichard, 2008).  
Thus, after this ban it is illegal to dose poultry with any fluoroquinolone and there is a 
zero tolerance level for residues in poultry in the United States (FDA, 2005; FDA, 2009).  
Although withdrawn, it is still possible for there to be illegal use of this antibiotic, which 
could result in enrofloxacin residues in edible poultry tissues.  
In an effort to protect consumers from potential toxic effects associated with 
concentrations of residues which exceed established tolerances in foods (e.g., antibiotic, 
pesticides or other chemicals), the U.S. Federal government has implemented specific 
programs to monitor for violative residues in food products and prevent their entrance 
into the food supply (FDA, 1997; Donoghue, 2003; Cerniglia and Kotarski, 2005; FSIS-
NRP, 2008).  In the specific case of monitoring of antibiotic residues in poultry meat 
products, it is the responsibility of the United States Department of Agriculture Food 
Safety and Inspection Service (USDA-FSIS) to ensure the safety and wholesomeness of 
these products, in accordance to the Poultry Products Inspection Act (PPIA; 21 U.S.C. 
451 et. seq.; FSIS, 2001; FDA, 2008; U.S. Code of Federal Regulations, 2010) and the 
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stipulations of the National Residue Program (USDA-FSIS-NRP).  The USDA-FSIS 
inspectors collect samples at the poultry processing plants for monitoring purposes and 
the tissue selected for monitoring is called the target tissue.  This is the tissue with the 
greatest antibiotic concentration and persistence, and for enrofloxacin in poultry, the 
imposed target tissue for residue monitoring is muscle (21CFR556.228, 2002) with the 
highest concentration in the breast muscle (Reyes-Herrera et al., 2005, Reyes-Herrera and 
Donoghue, 2008).  Because the monitoring process for enrofloxacin requires the 
collection and destruction of the muscle tissue for analysis, and due to this loss of product 
and the large number of birds being processed, the number of samples evaluated per flock 
is limited (see the sampling protocols for monitoring purposes, FSIS-NRP, 2008).  
Alternatively, the monitoring of enrofloxacin residues in blood in the processing plant 
could provide a fast and effective means to screen for the presence and concentrations of 
this antibiotic in a large number of processed poultry.  Blood samples are readily 
available from all birds at the beginning of processing, would be easy to collect, wouldn’t 
interfere with the processing procedure or require removal of the parts of the carcass and 
have no economic value.   
Previous work conducted to develop analytical methods to detect 
fluoroquinolones residues in chicken tissues (Schneider et al., 2007) indicated a potential 
relationship between blood and muscle concentrations.  Therefore, the objective of this 
follow-up study is the first in a series of studies to evaluate if blood antibiotic 
concentrations (in this case enrofloxacin) are predictive of residue concentrations in 
muscle tissues.  Because the target tissue for most antibiotics in poultry is muscle, these 
results may support the potential to use blood to screen for other antibiotic residues.   
 46
 
MATERIALS AND METHODS 
Enrofloxacin Dosing Protocol 
A total of 156 day-old male broiler chickens were obtained from a local hatchery 
and divided at random into two separate treatment groups.  All birds had ad libitum 
access to a standard non-medicated broiler diet (starter and grower) and non-medicated 
(pre-dosing period) or medicated water (dosing period).  Starting at day 33, the birds 
were dosed with enrofloxacin (Baytril®) in the drinking water, at either of the two 
different doses: 25µg mL-1  for 3 days or 50 µg mL-1 for 7 days, in accordance with the 
formerly FDA approved label directions for use of the antibiotic in poultry.  Medicated 
water was prepared fresh daily.  
 
Sample Collection and Preparation 
Blood and breast muscle samples were collected from 6 birds per group at each 
collection point.  Samples were collected immediately prior to initial dosing (controls, 
n=6 birds/2 pens); on day one of the dosing period samples were collected at 0, 1, 3, 6, 
12, 24 hours, and then every 48 hours until the end of the dosing period.  Finally, samples 
were collected every 12 hours for up to 60 hours post withdrawal.  All samples were 
processed individually; blood samples were collected in sterile test tubes, and allowed to 
clot for approximately 30 minutes at room temperature and then centrifuged (1,500 x g, 
10 min) to separate the serum fraction, which was then used for antibiotic determination.  
Serum and muscle samples were stored at -80°C until all the samples were collected.  
Muscle samples were homogenized using a standard tissue homogenizer (Omni 
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International).  All samples were diluted 1:3 (wt/vol) with 1% phosphate buffer, pH 9.0 
and centrifuged at 1,500 x g for 15 minutes at 5°C.  The supernatant was decanted and 
stored at -80°C until assayed.   
 
Sample Analysis  
All serum and muscle samples were analyzed for fluoroquinolone residues using 
the quantitative bioassay as described previously by our laboratories (Schneider and 
Donoghue (2004) and Reyes-Herrera and Donoghue (2008).  Briefly, on the day of the 
assay, Petri dishes (100 mm in diameter) were filled with 8 mL of Mueller-Hinton Agar 
inoculated with approximately 1x106 cfu/mL of Klebsiella pneumoniae (ATCC 10031), 
as indicator organism, and then 6 penicylinders (8x10mm) were evenly placed on the 
agar.  A standard curve was constructed by addition of known amount of enrofloxacin in 
buffer, with each standard concentration pipetted onto 3 plates; 3 alternate cylinders were 
filled with a known standard (200 µL each), and the other 3 cylinders were filled (200 µL 
each) with a reference concentration.  Individual samples were assayed in a similar 
manner to standards except samples were assayed on one plate.  Plates were incubated at 
37°C for approximately 16 h.  Plate averages for the standards and serum or muscle 
samples were corrected to the overall reference concentrations.  The lower limit of assay 
sensitivity was approximately 15 ng g-1.  A best-fit regression line was calculated by the 
method of least squares using the diameter of the inhibition zones (mm) with a zone 
reader (Fisher-Lilly, Pittsburgh PA).  
 
RESULTS 
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Fluoroquinolone residues were quantitated in all blood and muscle samples during 
the dosing periods and for up to 24 hours or 60 hours post-withdrawal for both dosing 
groups (Fig. 1-4).  The concentration of fluoroquinolone residues in muscle were higher 
than those in blood at every sampling time, both during the dosing (Figures 1 and 2) and 
withdrawal periods (Figures 3 and 4), for both treatment groups (low dose at 25 µg mL-1 
for 3 days and high dose at 50 µg mL-1 for 7 days).  After the first hour of dosing and for 
the first 24 hours after drug withdrawal, fluoroquinolone residues were approximately 
twice the concentration in muscle than blood.  Concentrations of residues peaked at day 3 
of the dosing period for both treatment groups (for the low dose group 710±64 ng g-1 or 
379±92 ng mL-1 for muscle versus blood, respectively, and for the high dose group 1538± 
97 ng g-1 or 705±59 ng mL-1 for muscle versus blood, respectively).   
 
DISCUSSION 
In this study, fluoroquinolone residues were detectable in both muscle and blood 
samples during both the dosing (Figures 1 and 2) and most of the withdrawal periods 
(Figures 3 and 4) which suggests that testing blood may be an effective strategy to screen 
for illegal enrofloxacin concentrations in poultry.  In addition, incorporation of data from 
the two tissues showed a similar kinetic update pattern of residue incorporation during 
the dosing and withdrawal periods, with quantifiable levels in muscle and blood starting 
at the first sampling period (1 hour) after dosing (Figures 1 and 2).   
The similarities between the incorporation patterns for blood versus muscle 
support not only the ability to use blood to screen for residues in muscle but also to 
estimate muscle residue concentrations.  Enrofloxacin has been described as having a 
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high tissue:blood concentration ratio (Garcia Ovando et al., 1999).  In this experiment we 
observed that the tissue:blood correlation for fluoroquinolone residues between chicken 
muscle and blood was approximately 2:1 for both treatment groups (25 µg mL-1 for 3 
days and 50 µg mL-1 for 7 days) during most of the dosing and withdrawal periods.  In 
other words, if a concentration of 100 ng mL-1 is determined in the blood, the 
concentration of fluoroquinolone residues in muscle would be estimated to be 
approximately 200 ng g-1.  This approximate relationship is consistent with results 
obtained from therapeutic efficacy (Knoll et al., 1999) or liquid chromatography-
fluorescence-mass spectrometry (HPLC/MS) methods development studies (Schneider et 
al., 2007) using incurred poultry blood and tissues samples.  
The only times residues were detected in muscle but not blood was when 
concentrations were extremely low by 36 hours after drug withdrawal for birds receiving 
the lowest dose of enrofloxacin (25 µg mL-1 / 3days).  Therefore, it is possible that at very 
low concentrations of enrofloxacin, evaluating blood would not accurately reflect illegal 
residues in muscle.  However, the ability to screen a greater number of poultry carcasses 
using blood, which would still identify the majority of enrofloxacin contamination, 
should be preferable to sampling only a small portion of carcasses for muscle 
contamination.  Furthermore, although the assay used in this study is considered 
reasonably sensitive (15 ng g-1), the development of more sensitive methods which could 
detect residues in blood at even lower concentrations could resolve this issue. 
The use of body fluids, such as blood, urine and kidney exudates, has also been 
proposed by several researchers to determine and monitor drug concentrations in live 
animals and in animal carcasses of swine (Ashworth et al., 1986); cattle (Lifschitz et al., 
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1999; Chiesa et al., 2006a; 2006b; Heller et al., 2006); sheep (Bevill et al., 1977a, 
1977b); elk (Clark et al., 2004) and poultry (Pant et al., 2005; Haasnoot et al., 2007; 
Schneider et al., 2007; 2009; Schneider and Lehotay, 2008).  Furthermore, this type of 
analysis is widely used to determine concentrations of drug levels in humans (Dickson et 
al., 1994; Rivier, 2000; Hammet-Stabler et al., 2002; Rigamonti et al., 2005).  With 
regards to poultry production, blood is available for sampling during standard activities at 
the processing plant and is a simple, inexpensive, relatively constant matrix to evaluate 
and does not require special, complicated or expensive preparations prior to analysis.  
Sampling blood may also eliminate many issues with specific tissue characteristics (e.g., 
muscle) which may complicate sample preparation and/or analysis (Okerman et al., 1998; 
Kubala-Drincic et al., 2003; Schneider et al., 2007).   
The use of blood samples as an initial screening method to detect illegal drug 
residues in animal carcasses could represent a simple and inexpensive option to detect 
adulterated food products, thus reducing the number of target tissue samples that would 
have to be collected and analyzed with the approved monitoring method (e.g., 
HPLC/MS).  Moreover, if the relationship between blood and the target tissue could be 
established for other antibiotics and veterinary drugs, this approach could increase the 
number of animals being tested at processing facilities and thus effectiveness of residue 
screening.  Additional studies are currently underway to determine if tissue:blood 
relationships determined in the present study apply to other antibiotics used in poultry.  
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Figure legends 
Figure 1. Concentrations of enrofloxacin residues determined during the dosing period (3 
days) from blood and breast muscle tissue samples collected from broiler chickens dosed 
with 25 µg mL-1 of enrofloxacin (n=42 birds).  Each time point represents the 
concentrations (average± SEM) from the samples collected from 6 birds. 
 
Figure 2. Concentrations of enrofloxacin residues determined during the dosing period 
from blood and breast muscle tissue samples collected from broiler chickens dosed with 
50 µg mL-1 of enrofloxacin for 7 days (n=54 birds).  Each time point represents the 
concentrations (average± SEM) from the samples collected from 6 birds. 
 
Figure 3. Concentrations of enrofloxacin residues determined during the withdrawal 
period (60 hours) from blood and breast muscle tissue samples collected from broiler 
chickens dosed with 25 µg mL-1 of enrofloxacin for 3 days (n=30 birds).  Each time point 
represents the concentrations (average± SEM) from the samples collected from 6 birds. 
 
Figure 4. Concentrations of enrofloxacin residues determined during the withdrawal 
period (60 hours) from blood and breast muscle tissue samples collected from broiler 
chickens dosed with 50 µg mL-1 of enrofloxacin for 7 days (n=30 birds).  Each time point 
represents the concentration (average± SEM) from the samples collected from 6 birds. 
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Figure 3 
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Figure 4 
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ABSTRACT 
 
The presence of antibiotic residues in edible animal products is a human food safety 
concern.  To address this potential problem, the government samples edible tissues, such 
as muscle, to monitor for residues.  Due to loss of valuable product and analytical 
difficulties only a small percentage of poultry carcasses are tested.  Alternatively, 
antibiotic residue concentrations could be screened in blood, which is readily available 
during carcass processing.  To determine if blood concentrations are predictive of muscle 
concentrations, 252 market aged broilers were dosed with the antibiotic oxytetracycline 
(OTC) in water at three doses: the maximum OTC approved dose for broilers (800 
mg/gal) or five or ten times that dose (4,000 or 8000mg/gal, respectively). Blood and 
muscle samples were collected prior to initial dosing (0 hour, controls), during the dosing 
period at 1, 3, 6, 12, 24, 48, 96 or 144 hours and at 12, 24, 36, 48 or 60 hours after drug 
withdrawal.   Residues of OTC in blood and muscle were determined using a microbial 
inhibition method.  Concentrations in both blood and muscle tissue followed similar time: 
concentration patterns, peaking 24 hours after initial dosing (396±9 vs. 557±37 ppb; 
1,443±48 vs. 1,846±58 ppb or 2,447±67 vs. 3,210±36 ppb for the 1, 5 or 10x doses in 
blood vs. muscle respectively) and declined rapidly after withdrawal.  These data suggest 
that blood samples may be used to predict OTC concentrations in muscle (by multiplying 
blood concentrations by 1.3) as a screening procedure for OTC residues in poultry.   
 
Keywords: Antibiotic residues, monitoring, oxytetracycline, blood: tissue ratio, chicken 
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INTRODUCTION 
The potential presence of antibiotic residues in food products is a major source of 
concern as they may induce adverse health effects in consumers (Bruhn, 1999; Gorbach 
2001; Tilman et al., 2002).  In an effort to prevent these problems, the Federal 
Government has developed strict protocols for the approval, use and monitoring of all 
veterinary drugs, particularly those used in food producing animals (Fink-Gremmels and 
van Miert 1994; Donoghue 2003; Hurtt et al., 2003; FDA, 2009).   
Monitoring procedures are based on sample collection and analysis of edible 
tissues at slaughter and processing facilities around the country (FSIS, 2009; FSIS-NRP, 
2009).  These samples are collected from the edible tissue with the highest concentration 
and longest persistence of the residues in the body (called the target tissue), and used as 
an indicator of the concentration of residues in the rest of the carcass, as stipulated in the 
Code of Federal Regulations (Brynes, 2005, Federal Register, 2001).   
Unfortunately, there are disadvantages using these procedures for sampling and 
analysis of samples for residue determination.  First, sample collection usually involves 
the destruction of the edible tissue used for testing, with subsequent monetary loss for the 
producers (Clement, 1995).  This is particularly true due to the large sample sizes which 
can be required for the determination of trace residues and contaminants in foods to 
improve the limits of detection of the assay (Ridgway et al., 2007).  Second, as the 
processing lines for poultry move at speeds of approximately 70-160 birds per minute 
(Berrang et al., 2007, 21CFR381, 2010), sample collection can be difficult. Finally, due 
to the great variability between the different potential types of tissues used for monitoring 
purposes (e.g. muscle, liver, kidney, skin, fat, etc.), the development of specific 
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procedures for sample preparation and analysis is required (Okerman et al., 1998; Elliot, 
2000; Andes and Craig, 2002; Berendsen and van Rhijn, 2006; Ridgway et al., 2007).  In 
some cases, sample preparation can become a major hurdle for sample analysis as it may 
involve extensive sample extraction and/or the use of potentially toxic chemicals (e.g. 
solvents; Kubala-Drincic et al., 2003; Ridgway et al., 2007).  Thus, the development of 
an initial screening strategy that could provide simple and reliable indication of the 
concentration of the residues in the target tissue without the need to undergo extensive 
extraction procedures or specific modifications due to matrix and antibiotic properties, 
could expedite sampling and screening activities.  Additionally, such a method could also 
potentially reduce the effort, cost and time involved in this process and increase the 
efficiency of the monitoring procedures.  
To overcome these problems several researchers have proposed the use of body 
fluids (e.g. bile, urine, kidney exudates, blood) to verify and monitor drug concentrations 
in live animals and carcasses at processing plants, such as those of swine (Ashworth et 
al., 1986); cattle (Mercer et al., 1977; Meijer et al., 1993; Lifschitz et al., 1999; Chiesa et 
al., 2006a; 2006b; Heller et al., 2006); sheep (Bevill et al., 1977; Delis et al., 2009); elk 
(Clark et al., 2004) and poultry (Dyer , 1988, 1989; Farrington et al., 1991; Moreno et al., 
1996; Pant et al., 2005; Haasnoot et al., 2005; 2005b; Haasnoot et al., 2007; Schneider et 
al., 2007a; 2007b; 2009; Schneider and Lehotay, 2008).  Additionally, this type of 
analysis is widely used to determine concentrations of drug levels in humans (Dickson et 
al., 1994; Rivier, 2000; Hammet-Stabler et al., 2002; Kim et al., 2002; Rigamonti et al., 
2005).   
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Previous studies conducted in our laboratory evaluated the relationship between 
blood and muscle concentrations for the fluoroquinolone antibiotic, enrofloxacin, in 
broiler chickens (Schneider et al., 2007a; Reyes-Herrera et al., 2010).  Blood is readily 
available at poultry processing plants and does not require removal or destruction of 
edible tissues from poultry carcasses.  It was determined that the concentrations of 
fluoroquinolone residues in blood were a reliable predictor of the concentrations of 
residues in muscle (Reyes-Herrera et al., 2010).  Thus, at least in the case of enrofloxacin 
in broiler chickens, blood samples could potentially be used as a tool for initial screening 
procedures to identify potentially adulterated carcasses that could then be tested with 
more specific monitoring procedures. 
The objective of the current study was to evaluate if concentrations of 
oxytetracycline (OTC) concentrations in blood could provide a reliable estimate of 
residue concentrations in muscle (target tissue).  Furthermore, the pattern of 
incorporation of OTC residues was compared with results previously obtained for 
enrofloxacin to evaluate if there are similarities between different classes of antibiotics.  
If there is a relationship, it may be possible to model (predict) residue concentrations for 
a wide variety of antibiotics.  Oxytetracycline was evaluated in this study because 
tetracyclines are some of the most widely used class of antibiotics in the poultry industry 
and have been reported to produce violative residues in chicken muscle samples (De 
Wasch et al., 1998, Chopra and Roberts, 2001; Okerman et al., 2001; Oka et al., 2001; 
Okerman et al., 2004).   
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MATERIALS AND METHODS 
A total of 252 day-old meat-type chickens were obtained from a local commercial 
hatchery and divided at random into three separate treatment groups.  Birds had ad 
libitum access to a standard broiler diet and water during the entire experiment.  Starting 
at day 33 of age, birds were dosed with oxytetracycline dihydrate (Sigma-Aldrich) in the 
drinking water at one of three different doses: 800 mg/gal (211 mg/L) the maximum 
approved dose (1X) for this antibiotic (FOI, 2005; 21 CFR520.1660, 2010), and then 5 
times (5X) or 10 times (10X) the approved dose: 4,000 mg/gal (1,056 mg/L) or 8,000 
mg/gal (2,113 mg/L) to investigate the kinetics of the drug at concentrations close to the 
imposed tolerance limit for this drug in the target tissue.  Medicated water was prepared 
daily. 
Blood and breast muscle samples were collected from 6 birds per group at each 
collection point.  Samples were collected immediately before initial dosing (0 hour, 
controls) and during the dosing period at 1, 3, 6, 12, 24, 48, 96 or 144 hours and then at 
12, 24, 36, 48 or 60 hours after drug withdrawal.  All samples were processed 
individually as previously described (Reyes-Herrera et al., 2010).  Blood samples were 
collected in sterile test tubes and then centrifuged (1,500 x g, 10 min) to separate the 
serum fraction, which was then used for antibiotic determination.  Muscle samples were 
homogenized using a standard tissue homogenizer (Omni International).  All samples 
were diluted 1:3 (wt/vol) with 1% phosphate buffer, pH 9.0 and centrifuged at 1,500 x g 
for 15 minutes at 5°C.  The supernatant was decanted and stored at -80°C until assayed.   
All blood and muscle samples were analyzed for oxytetracycline residues 
according to the approved method for oxytetracycline analysis from the USDA-FSIS, 
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Laboratory QA/QC Division (2007) with modifications (Donoghue et al., 1996).  Briefly, 
on the day of the assay, Antibiotic Media No. 8 (Benton, Dickinson & Co.) was prepared, 
according to manufacturer instructions, and inoculated with the required quantity of 
Bacillus cereus spores (ATCC 11778; MEDTOX Diagnostics, Inc.) into the agar to make 
a final concentration of 5x103 cfu/mL of indicator bacteria in the agar.  The inoculated 
media was incubated for 45 minutes in a 48±2°C water bath before addition of 1.0 mL of 
penicillinase concentrate per 100 ml of seeded media (Becton, Dickinson & Co).  Petri 
dishes (100 mm in diameter) were filled with 8 mL of inoculated media and then six 
penicylinders (8x10mm) were evenly placed on the agar.  A standard curve was 
constructed by dilution of oxytetracycline in 0.01 N hydrochloric acid to produce a 1,000 
ppm (parts per million or µg/ml) stock solution and further diluted using a 0.1M pH 4.5 
phosphate buffer.  Each standard concentration was pipetted onto three plates; three 
alternate cylinders were filled with a known standard (200 µL each), and the other three 
cylinders were filled with the overall reference concentration standard (200 µL each).  
The overall reference concentration falls within the range of the standard curve.  
Individual samples were assayed in a similar manner to that of the standard curve, except 
samples were assayed on only one plate.  Plates were incubated at 29±1°C for 
approximately 16 hours.  Plate averages for the standards, blood or muscle samples were 
corrected to the overall reference concentrations.  A best-fit regression line was 
calculated by the method of Least Squares using the diameter of the inhibition zones 
(mm) with a zone reader (Fisher-Lilly, Pittsburgh PA).  The assay detection limit was 68 
ppb.  
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RESULTS  
Oxytetracycline residues were detected in both blood and muscle tissue during all 
collection points during the dosing period [Figures 1, 2 and 3] and withdrawal period 
[Figures 4a and 4b], except for the withdrawal period of the 1X dosing group.  In the 1X 
group, residues were detectable during the withdrawal period only in muscle (76±8 ppb) 
at 12 hours after drug withdrawal.  Controls (samples collected prior to the beginning of 
the dosing period) were also negative for oxytetracyclines residues. 
The residue concentrations of oxytetracyclines in muscle were higher than those 
in blood in all samples during the dosing and withdrawal period, except in the case of 
samples collected 1 hour after the beginning of the dosing when blood concentrations 
were slightly higher than those in muscle (212±13 vs. 177±10 ppb [Figure 1]; 327±21 vs. 
251±18 ppb [Figure 2]; 726±42 vs. 317±51 ppb [Figure 3], for the 1X, 5X or 10X dosing 
groups, blood or muscle respectively).  Oxytetracycline concentrations peaked in both 
blood and muscle at 24 hours during the dosing period for all treatment groups.  The 
concentration of the antibiotic declined rapidly in both blood and muscle after drug 
withdrawal in all dosing groups.  Oxytetracycline residues were not-detectable after 12 
hours in the case of the birds treated with the approved dose of the oxytetracycline (1X), 
while the results for the other two treatments are shown in Figures 4a and 4b.   
 
DISCUSSION 
Results from this study support the potential use of blood to predict violative 
residues of oxytetracycline in muscle.  By the third hour after oxytetracycline 
administration in the drinking water, there was a consistent relationship between blood 
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and muscle residue concentrations during the dosing period for birds receiving the 
maximum allowed dose for OTC in broiler chickens (800 mg/gal) or 5 or 10 times that 
dose.  During the dosing period, the muscle concentrations were approximately 1.2 to 1.5 
times higher than in blood for all three different dosing treatments (Figures 1, 2 and 3) 
and exceeded the FDA established tolerance in muscle (2,000 ppb) only for the chickens 
receiving the 10x dose (Figure 3).  Upon drug withdrawal, oxytetracycline residue 
concentrations were undetectable in the 1x dosing group and dropped rapidly in the 5 and 
10 x treatment groups (Figure 4).  For oxytetracycline, the FDA established tolerance for 
residues in poultry muscle is 2,000 ppb (Arkin, 2005; FOI, 2005; 21CFR556.500b.1, 
2010).  Our results indicate that when blood concentrations approach or exceed 1,500 
ppb, muscle residue concentrations are close to or in excess of the 2,000 ppb tolerance 
(Figures 2, 3).  Thus, federal regulators could use blood samples to screen for 
oxytetracycline residues and any blood concentrations approaching or exceeding 1,500 
ppb would trigger testing of carcasses for muscle residue determination. 
These results are in agreement with previous studies conducted in our laboratory 
evaluating the relationship between blood and muscle concentrations for the 
fluoroquinolone antibiotic, enrofloxacin (Reyes-Herrera et al., 2010).  In those studies, 
we also found that antibiotic concentrations in muscle were higher than in blood and 
blood concentrations were predictive of muscle concentrations.  Although this 
relationship appears consistent for two different classes of antibiotics, it is possible that 
other antibiotic classes may behave differently.  Factors such as specific tissue and 
protein binding affinities of an antibiotic and its lipophilicity, which determines its 
incorporation into the intracellular space, are important factors to consider (Ashworth et 
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al., 1986; Ryan et al., 1986).  Depending on these factors the relationship between the 
concentration of residues in blood and the target tissue may vary.  For example, due to 
their non-lipophilic nature, most β-lactams do not penetrate the cells and are confined to 
the extracellular fluids causing higher concentration of residues in blood than in tissue 
(namely muscle; Ryan et al., 1986; Li et al., 1995).  Alternatively, the residue 
concentration may reach higher concentrations in muscle than in blood, as is the case of 
oxytetracyclines in poultry as shown in this study.  Other antibiotics with higher 
concentrations in muscle are enrofloxacin (Knoll et al., 1999; Reyes-Herrera et al., 2010); 
flumequine (Haasnoot et al., 2007), and sulfonamides (Haasnoot et al., 1996; 2005a; 
2005b).  For instance, the blood concentrations of sulfamethoxazole and sulfadiazine are 
6.2 and 8.7 times higher than those in muscle (Haasnoot et al., 2005b).   
Moreover, for some antibiotics the blood:tissue relationship will vary significantly 
depending on the specific tissue.  For example, even though the tetracyclines appear to 
behave as a two-compartment model with higher concentrations in muscle than in blood, 
the same antibiotic can almost irreversibly bind to bone and teeth (acting as a three or 
four compartment model) and thus blood levels will not provide an indication of 
antibiotic concentrations in these tissues (Anadón et al., 1985; Shish, 2009).  This is of 
particular importance if bone meal from tetracycline treated animals is used to feed 
animals (still practiced in some countries).  This practice has been identified as one 
potential source of unintentional exposure to tetracyclines for food producing animals 
(Kuhne et al., 2000; Korner et al., 2001).  Another antibiotic group with similar complex 
compartmentalization patterns are the aminoglycosides (e.g. gentamicin, amikacin and 
neomycin), which tend to form irreversible binding to intracellular organelles in the 
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kidney cortex and cochlear tissues in the ear, and thus residues in these organs will persist 
for long periods of time even after they become non-detectable in blood levels (Nix et al., 
1991; Chiesa et al., 2006a, 2006b).  Consequently, in the case of these antibiotics, blood 
samples may not serve as reliable indicators of the concentration of these sequestered 
residues.  These potential variations in the blood: tissue relations for different classes of 
antibiotics suggest the need for the study and characterization of each antibiotic of 
interest.  However, since the study of the pharmacological profile of most veterinary 
drugs are conducted as part of the New Animal Drug Application approval process 
(including pharmacokinetic, pharmacodynamic and tissue distribution determinations; 
Clement, 1995; NRC, 1999; FDA, 2009), that information could be obtained and used by 
monitoring personnel.   
The results from this study also demonstrate that oxytetracycline residues will not 
exceed the tolerance when the approved dose of this antibiotic (800 mg/gal) is used in 
broiler chickens (Figure 1).  Yet, this class of antibiotic has been reported to produce 
violative residues in chicken muscle samples (De Wasch et al., 1998, Chopra and 
Roberts, 2001; Okerman et al., 2001; Oka et al., 2001; Okerman et al., 2004; FSIS, 2005; 
FSIS, 2008).  These violations may be due to a failure to understand or follow label 
instructions when dosing food producing animals (Riviere, 1991, Brynes and Weber, 
1996; FDA, 2005; FDA, 2009; FSIS-NRP, 2009).  Because of these potential problems, 
monitoring is still necessary to ensure the safety of our food supply.  
In conclusion, the use of blood samples as a potential initial screening method to 
detect harmful concentrations of antibiotic residues in poultry muscle could provide 
reliable estimations of the concentration of different antibiotic residues in target tissues 
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without the need for tissue collection and destruction for monitoring purposes.  Although 
blood residues concentrations were predictive of muscle concentrations for both 
oxytetracycline and enrofloxacin (previous work), the blood:muscle relationships should 
be determined for other antibiotics of interest to determine the utility of blood to predict 
residues exceeding tolerances in edible tissues.  
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Figure legends 
Figure 1. Concentrations of oxytetracycline residues determined during the dosing period 
from blood or breast muscle tissue samples collected from broiler chickens dosed with 
the approved dose for OTC for broiler chickens (800 mg/gal).  Each time point represents 
the OTC concentrations (average± SEM) from 6 birds. 
 
Figure 2. Concentrations of oxytetracycline residues determined during the dosing period 
from blood or breast muscle tissue samples collected from broiler chickens dosed with 
the five times (4,000 mg/gal) the approved dose for OTC for broiler chickens.  Each time 
point represents the OTC concentrations (average± SEM) from 6 birds.  The tolerance for 
OTC in muscle of broilers (2,000 ppb) is indicated by a dashed line. 
 
Figure 3. Concentrations of oxytetracycline residues determined during the dosing period 
from blood or breast muscle tissue samples collected from broiler chickens dosed with 
ten times (8,000 mg/gal) the approved dose for OTC for broiler chickens.  Each time 
point represents the OTC concentrations (average± SEM) from the samples collected 
from 6 birds.  The tolerance for OTC in muscle of broilers (2,000 ppb) is indicated by a 
dashed line.   
 
Figure 4. Concentrations of oxytetracycline residues determined during the withdrawal 
period from blood or breast muscle tissue samples collected from broiler chickens dosed 
with 5 (Fig. 4a) or 10 times Fig. 4b) the approved dose of OTC for broiler chickens 
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(4,000 mg/gal or 8,000 mg/gal in the drinking water, respectively).  Each time point 
represents the OTC concentrations (average± SEM) from 6 birds.   
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Figure 3 
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Figure 4 
0
100
200
300
400
500
600
700
12 hrs 24 hrs 36 hrs 48 hrs 60 hrs
COLLECTION TIM ES
Blood
Muscle
0
500
1000
1500
2000
12 hrs 24 hrs 36 hrs 48 hrs 60 hrs
COLLECTION TIM ES
Blood
Muscle
C
on
ce
nt
ra
tio
n 
of
 te
tra
cy
cl
in
es
 (p
pb
)
C
on
ce
nt
ra
tio
n 
of
 te
tra
cy
cl
in
es
 (p
pb
)
a.
b.
C
on
ce
nt
ra
tio
n 
of
 te
tra
cy
cl
in
es
 (p
pb
)
C
on
ce
nt
ra
tio
n 
of
 te
tra
cy
cl
in
es
 (p
pb
)
 
 
 
 
 
 
 
 79
REFERENCES 
21CFR381. 2010. Poultry products inspection regulation. Subpart K. Post mortem 
inspection. Disposition of carcasses and parts. Code of Federal Regulations. 
http://frwebgate3.access.gpo.gov/cgi-bin/PDFgate.cgi.  Accessed July 2010. 
 
21CFR520.1660d, 2010. Oral dosage form of new animal drugs. Sec. 520.1660d 
Oxytetracycline powder. Code of Federal Regulations.  
http://edocket.access.gpo.gov/cfr_2010/aprqtr/pdf/21cfr520.1660d.pdf.  Accessed 
July 2010. 
 
21CFR556.228, 2002. Tolerances for residues of new animal drugs in foods. 
Enrofloxacin. Code of Federal Regulations. http://frwebgate3.access.gpo.gov/cgi-
bin/PDFgate.cgi.  Accessed July 2010. 
 
21CFR556.500b.1, 2010. Tolerances for residues of new animal drugs in food. Code of 
Federal Regulations. http://www.access.gpo.gov/nara/cfr/waisidx_10/ 
21cfr556_10.html.  Accessed July 2010. 
 
Anadón, A, M. R. Martinez-Larrañaga and M.J. Diaz. 1985. Pharmacokinetics of 
tetracycline in chickens after intravenous administration. Poult. Sci.. 64:2273-
2279.  
 
Andes, D. and W.A. Craig. 2002. Animal model pharmacokinetics and 
pharmacodynamic: a critical review. Int. J. Antimicrob. Ag. 19:261-268. 
 
Arkin, R.L. 2005. CVM researchers use latest science to develop methods for detecting 
animal drug residues FDA Veterinarian Newsletter. Volume XX No. I. 
http://www.fda.gov/AnimalVeterinary/NewsEvents/FDAVeterinarianNewsletter/
ucm092045.htm. Accessed August 2010. 
 
Ashworth, R.B., R.L. Epstein, M.H. Thomas, and L.T. Frobish. 1986. Sulfamethazine 
blood/tissue correlation study in swine. Am. J Res. Vet. 47(12): 2596-2603. 
 
Berendsen, B.J.A. and J.A. van Rhijn.  2006.  Residue analysis of tetracyclines in poultry 
muscle: shortcomings revealed by a proficiency test. Food Addit. Contam. 
23:1141-1148. 
 
Berrang, M. E., J. S. Bailey, S. F. Altekruse, B. Patel, W. K. Shaw, R. J. Meinersmann 
and P. J. Fedorka-Cray.  2007.  Prevalence and numbers of Campylobacter on 
broiler carcasses collected at rehang and postchill in 20 U.S. processing plants. J. 
Food Prot. 70:1556-1560. 
 
Bevill, R.F., R.M. Sharma, S.H. Meachum, S.C Wozniak, D.W.A. Bourne and L.W. 
Dittert. 1977. Disposition of sulfonamides in food-producing animals: 
 80
Concentrations of sulfamethazine and its metabolites in plasma, urine and tissues 
of lambs following intravenous administration. Am. J. Vet. Res. 38: 973-977. 
 
Bruhn, C.M. 1999. Consumer perceptions and concerns about food contaminants. Adv 
Exp Med Biol.459:1-7. 
 
Brynes, S.D. 2005. Demystifying 21 CFR Part 556- Tolerances for residues of new 
animal drugs in foods. Reg. Toxicol. Pharmacol. 42:324-327. 
 
Brynes, S.D. and N.E. Weber. 1996. Residues of veterinary drugs and mycotoxins in 
animal products. Wageningen Press. Wageningen, The Netherlands  
 
Chiesa, O.A., J. von Bredow, D. Heller, C. Nochetto, M. Smith, K. Moulton and M. 
Thomas. 2006a. Use of tissue-fluid correlations to estimate gentamicin residues in 
kidney tissue of Holstein steers. J. Vet. Pharmacol. Therap. 29:99-106. 
 
Chiesa, O.A., J. von Bredow, M. Smith, D. Heller, R. Condon and M.H. Thomas. 2006b. 
Bovine kidney tissue/biological fluid correlation for penicillin. J. Vet. Pharmacol. 
Therap. 29:299-306. 
 
Chopra, I. and M. Roberts. 2001. Tetracycline antibiotics: mode of action, application, 
molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol 
Rev 65:232–260.  
 
Clark, C., M. Woodbury, P. Dowling, S. Ross and J.O. Boison. 2004. A preliminary 
investigation of the disposition of tilmicosin residues in elk tissues and serum. J 
Vet Pharmacol Ther. 27:385-387.  
 
Clement, R. P. 1995. Preclinical drug metabolism programs for food-producing animals. 
Toxicol. Pathol. 23:209-216. 
 
De Ruyck, H., H. De Ridder, R. van Renterghem and F. van Wambeke. 1999. Validation 
of HPLC method of analysis of tetracycline residues in eggs and broiler meat and 
its application to a feeding trial. Food. Addit. Contam. 16:47-56. 
 
De Wasch, K., L. Okerman, S. Croubels, H. De Brabander, J. Van Hoof, P. De Backer. 
1998. Detection of residues of tetracycline antibiotics in pork and chicken meat: 
correlation between results of screening and confirmatory tests. Analyst. 
123:2737-2741. 
 
Delis, G., G. Batzias, G. Kounenis and M.Koutsoviti-Papadopoulou. 2009. Application 
and validation of a LC/fluorescence method for the determination of amoxicillin 
in sheep serum and tissue cage fluid. J Pharm Biomed Anal. 49:375-380.  
 
 81
Dickson, P.H., A. Lind, P. Studts, H.C. Nipper, M. Makoid, and D. Therkidsen. 1994. 
The routine analysis of breast milk for drugs of abuse in a clinical toxicology 
laboratory. J. Foren. Sci. 39:207-214. 
 
Donoghue, D. J., H. Hairston, S. Gaines, M. J. Bartholomew and A. M. Donoghue.  1996. 
Modeling residue uptake in eggs. Similar drug residue patterns in developing 
yolks following injection with ampicillin or oxytetracycline. Poult. Sci. 75:321-
328. 
 
Donoghue, D.J. 2003. Antibiotic residues in poultry tissues and eggs: Human health 
concerns? Poult. Sci. 82:618-621. 
 
Dyer, D.C. 1988. Pharmacokinetics of chlortetracycline in the turkey: evaluation of 
biliary secretion. Am. J. Vet. Res. 49:36-37. 
 
Dyer, D.C. 1989. Pharmacokinetics of oxytetracycline in the turkey: evaluation of biliary 
and urinary excretion. Am. J. Vet. Res. 50: 522-524. 
 
Elliot, C.T. 2000. Fast automated screening systems for veterinary drug residues. IV 
Euroresidue Conference. http://www.euroresidue.nl/previous.html. Accessed July 
2010. 
 
Farrington W.W.H., J. Tarbin, and G. Sheraer. 1991. Analysis of trace residues of 
tetracyclines in animal tissues and fluids using metal chelate affinity 
chromatography/HPLC. Food Addit. Contam. 8:595–614 
 
FDA, 2005.  Food and Drug Administration: Compliance program guidance manual.  
Post approval monitoring of animal drugs, feeds and devices. Illegal residues in 
meat, poultry, seafood, and other animal derived foods. 
http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcem
ent/ComplianceEnforcement/ucm113433.pdf. Accessed July 2010. 
 
FDA, 2009. CPG Sec. 615.200  Food and Drug Administration.  Proper drug use and 
residue avoidance by non-veterinarians (CPG 7125.37) Page 354 
http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidance 
Manual/ucm074660.htm. Accessed July 2010. 
 
Federal Register, 2001. Notices. Department of Agriculture. Food Safety and Inspection 
Service. Residue Testing Procedures. Notice. Vol. 66(151):40964-40965.  August 
6. http://www.fsis.usda.gov/ oppde/rdad/FRPubs/00-051N.htm. Accessed July 
2010. 
Fink-Gremmels, J. and A.S. van Miert. 1994. Veterinary drugs: disposition, 
biotransformation and risk evaluation. Analyst. 119:2521-2528. 
 
FOI.  2005.  Freedom of information Summary. Original Abbreviated new animal drug 
application. ANDADA 200-374.  Tetracycline hydrochloride.  
 82
http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDru
gProducts/FOIADrugSummaries/ucm059306.pdf. Accessed July 2010. 
 
FSIS, 2005. Food Safety and Inspection Service National Residue Service Data. Red 
Book.  www.fsis.usda.gov/Science/2005_Red_Book /index.asp. Accessed August 
2010. 
FSIS, 2008. Food Safety and Inspection Service National Residue Service Data Red 
Book. www.fsis.usda.gov/PDF/2008_Red_Book.pdf. Accessed July 2010. 
 
FSIS, 2009. Poultry Products Inspection Act. Title 21 Food and Drugs. Chapter 10: 
Poultry and poultry products inspection. http://www.fsis.usda.gov/ 
regulations_&_policies/PPIA/index.asp#Sec. 455. Accessed August 2010. 
 
FSIS-NRP, 2009. Food Safety and Inspection Service. 2009 FSIS National Residue 
Program Scheduled Sampling Plans. http://www.fsis.usda.gov/PDF/ 
2009_Blue_Book.pdf. Accessed July 2010. 
 
Gorbach, S.L. 2001. Antimicrobial use in animal feed--time to stop. N. Engl. J Med. 
345:1202-1203. 
 
Haasnoot, W., G.O. Korsrud, G, Cazemier, F, Maneval, H, Keukens and J.Nouws. 1996. 
Application of an enzyme immunoassay for the determination of sulphamethazine 
(sulphadimidine) residues in swine urine and plasma and their use as predictors of 
the level in edible tissue. Food Addit. Contam. 13:811-821. 
 
Haasnoot, W., H. Gercek, G. Cazemier and M.W. F. Nielen. 2007. Biosensor 
immunoassay for flumequine in broiler serum and muscle. Anal. Chim. Acta 
586:312-318. 
 
Haasnoot, W., M. Bienenmann-Ploum, T. Korpim¨aki, G. Cazemier, J. du Pre, F. Kohen.  
2005a. Biosensor detection of sulfonamides: From specific to multi-sulfonamide 
assays In: Rapid Methods for Biological and Chemical Contaminants in Food and 
Feed (A. van Amerongen, D. Barug, M. Lauwaars; Eds.), Wageningen Academic 
Publishers, Wageningen, The  Netherlands, pp. 321–337. 
 
Haasnoot, W., M.E. Ploum, U. Lamminmaeki, M. Swanenburg and J.A. van Rhijn. 
2005b. Application of a multi-sulfonamide biosensor immunoassay for the 
detection of sulfadiazine and sulfamethoxazole residues in broiler serum and its 
use a as a predictor of the levels in edible tissue. Anal. Chim. Acta. 552:87-95. 
 
Hammet-Stabler, C.A., A.J. Pesce and D.J. Cannon. 2002. Urine drug screening in the 
medical setting. Clin. Chim. Acta 315:125-135. 
 
Heller, D. M.L. Smith, and O.A. Chiesa. 2006. LC/MS/MS measurement from penicillin 
G in bovine plasma, urine and biopsy samples taken from kidneys in standing 
animals. J Chromatogr B Analyt Technol Biomed Life Sci. 830:91-99. 
 83
 
Hurtt, M.E., G.D. Cappon and A. Browning. 2003. Proposal for a tiered approach to 
developmental toxicity testing for veterinary pharmaceutical products for food-
producing animals. Food Chem Toxicol. 41:611-619.  
 
Kim, I., A.J. Barnes, J.M. Oyler, R. Schepers, R.E. Joseph, E.J. Cone, D. Lafko, E.T. 
Moolchan and M.A. Huestis. 2002. Plasma and oral fluid pharmacokinetics and 
pharmacodynamics after oral codeine administration. Clin. Chem. 48:1486-1496. 
 
Knoll, U., G. Glunder and M. Kietzmann.1999. Comparative study of the plasma 
pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in 
broiler chickens. J. Vet. Pharmacol. Therap. 22:239-246. 
 
Korner, U., M. Kuhne and S. Wenzel. 2001. Tetracycline residues in meat and bone 
meals. Part 1: Methodology and examination of field samples. Food Addit. 
Contam. 18:293-302. 
 
Kubala-Drincic, H., D. Bazulic, J. Sapunar-Postruznik, M. Grubelic and G. Stuhne. 2003. 
Matrix solid-phase dispersion extraction and gas chromatographic determination 
of chloramphenicol in muscle tissue. J Agric Food Chem. 51:871-875.  
 
Kuhne, M., S. Wegmann, A. Kobe and R. Fries. 2000. Tetracycline residues in bones of 
slaughtered animals. Food Control. 11:175-180.  
 
Li, T., G.L. Qiao, G.Z. Hu, F.D. Meng, Y.S Qiu, X.Y. Zhang, W.X. Guo, H.L. Yie, S.F. 
Li and S.Y. Li. 1995. Comparative plasma and tissue pharmacokinetics and drug 
residue profiles of different chemotherapeutants in fowls and rabbits. J.Vet. 
Pharmacol. Therap. 18: 260-273. 
 
Lifschitz, A., G. Virkel, F. Imperiale, J.F. Sutra, P. Galtier, C. Lanusse and M. Alvinerie. 
1999. Moxidectin in cattle: Correlation between plasma and target tissues 
disposition. J. Vet. Pharmacol. Therap. 22:266-273. 
 
Meijer, L.A., K.G.F. Ceyssens, W.T. de Jong and B.I.J.A.C. de Greve. 1993. Correlation 
between tissue and plasma concentrations of oxytetracycline in veal calves. J. 
Toxicol. Environ. Health A. 40:35-45. 
 
Mercer, H.D., L.D. Rollins, G.G. Carter, R.P. Gural, D.W. Bourne, L.W. Dittert. 1977.  
Factors affecting serum oxytetracycline levels in beef calves. J Pharm Sci. 
66:1198-1200. 
 
Moreno, L. L.M. Serrano, A. Reja, E. Guimeraâ, and E. Escudero. 1996. 
Pharmacokinetics of oxytetracycline after intravenous administration at two dose 
levels to hens. J. Vet. Pharmacol. Therap. 19:495-497. 
 
 84
Nix, D.E., S.D. Goodwin, C.A. Peloquin, D.L. Rotella and J.J. Schentag. 1991. Antibiotic 
tissue penetration and its relevance: impact of tissue penetration on infection 
response. Antimicrob. Agents Chemother. 35:1953-1959. 
 
NRC. 1999. National Research Council. The use of drugs in food animals: benefits and 
risks. National Academy Press, Washington, DC. 
 
Oka, H., Y. Ito, Y. Ikai, H. Matsumoto, K. Kato, I. Yamamoto, M. Shimizu, N. 
Kawamura, Y. Miyazaki, T. Nojiri, M. Okumura, S. Ohmi, T. Sato and G. Mori.  
2001.  Survey of residual tetracyclines in kidneys of diseased animals in Aichi 
Prefecture, Japan (1985-1997). J AOAC Int. 2001 84:350-353. 
 
Okerman, L., K. De Wasch and J. Van Hoof. 1998. Detection of antibiotics in muscle 
tissue with microbiological inhibition tests: effects of the matrix.  Analyst. 
123:2361-2365. 
 
Okerman, L., S. Croubels, M. Cherlet, K. De Wasch, P. De Backer and J. Van Hoof.  
2004.  Evaluation and establishing the performance of different screening tests for 
tetracycline residues in animal tissues.  Food Addit. Contam., 21:145–153. 
 
Okerman, L., S. Croubels, S. De Baere, J. Van Hoof, P. De Backer and H. De Brabander. 
2001. Inhibition tests for detection and presumptive identification of tetracyclines, 
beta-lactam antibiotics and quinolones in poultry meat. Food Addit. Contam. 
18:385-393. 
Pant, S., G.S.Rao, K.V.H. Sastry, H.C. Tripathi, R. Jagmohan and J.K. Malik. 2005. 
Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin 
in broiler chickens. Brit. Poult. Sci. 46: 615-620. 
 
Reyes-Herrera, I., M.J. Schneider, P.J. Blore and D.J. Donoghue.  2010.  The relationship 
between blood and muscle samples to monitor for illegal residues of the antibiotic 
enrofloxacin in chickens. Poult. Sci. In press. 
 
Ridgway, K., S.P.D. Lallje and R.M. Smith. 2007. Sample preparation techniques for the 
determination of trace residues and contaminants in foods. J. Chromatograph. A. 
1153:36-53. 
 
Rigamonti, A.E., S.G. Cella, N. Marazzi, L. Di Luigi, A. Sartorio and E.E. Müller. 2005. 
Growth hormone abuse: methods of detection. Trends Endocrinol Metab. 16:160-
166.  
Rivier, 2000. Techniques for analytical testing of unconventional samples. Baillieres Best 
Pract Res Clin Endocrinol Metab. 14:147-165. 
 
Riviere, J.E. 1991. Pharmacologic principles of residue avoidance for veterinary 
practitioners. JAVMA 198:809-815. 
 
 85
Riviere, J.E. 2003. Compartmental models. In: Comparative pharmacokinetics: 
Principles, techniques and applications. Wiley-Blackwell. 
 
Ryan, M.D., O. Cars and B. Hoffstedt. 1986. The use of antibiotic serum levels to predict 
concentrations in tissues. Scand. J. Infect. Dis. 18:381-388. 
 
SAS Institute.  2002.  SAS/STAT® User’s guide:  Release 9.03 edition.  SAS Institute 
Inc., Cary, NC. 
 
Schneider, M.J. and S.J. Lehotay. 2008. A comparison of the FAST, Premi and KIS tests 
for screening antibiotic residues in beef kidney juice and serum. Anal Bioanal 
Chem. 390:1775-1779.  
 
Schneider, M.J., I. Reyes-Herrera and D.J. Donoghue. 2007a. Evaluation of serum as a 
potential matrix for multiresidue determination of fluoroquinolone antibiotics in 
chicken using liquid chromatography-fluorescence-mass spectrometry (n). J 
AOAC Int. 90:1716-1723. 
 
Schneider, M.J., K. Mastovska, S.J. Lehotay, A.R. Lightfield, B. Kinsella and C.E. 
Shultz. 2009. Comparison of screening methods for antibiotics in beef kidney 
juice and serum. Anal Chim Acta. 637:290-297.  
 
Schneider, M.J., S.E. Braden, I. Reyes-Herrera and D.J. Donoghue. 2007b. Simultaneous 
determination of fluoroquinolones and tetracyclines in chicken muscle using 
HPLC with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life 
Sci. 846:8-13.  
 
Serrano, J.M., L.Moreno, I. Rosado, E. Guimerâ and E. Escudero.  1999.  Biliary 
elimination kinetics and tissue concentrations of oxytetracycline after intravenous 
administration in hens.  J. Vet. Pharmacol. Therap.22:148-152. 
 
Shih, M.S. 2009. Bone histomorphometry and undecalcified sections. In: Bone Pathology 
(Jasvir S. Khurana, Ed.) Humana Press. Pp. 129-138. 
 
Tilman, D., K.G. Cassman, P.A. Matson, R. Naylor and S. Polasky. 2002. Agricultural 
sustainability and intensive production practices. Nature. 418:671-677.  
 
USDA-FSIS, Laboratory QA/QC Division (2007). Laboratory guidebook: Bioassay for 
the detection, identification and quantitation of antimicrobial residues in meat and 
poultry tissue http://www.fsis.usda.gov/ PDF/MLG_34_02.pdf Accessed July 
2010. 
 
 86
 
 
 
 
 
 
 
 
 
CHAPTER IV 
CONCLUSION 
 
 87
The potential use of blood samples as a screening tool for monitoring antibiotic 
residues in poultry edible tissues 
 
The presence of antibiotic residues in edible animal products is a human food 
safety concern. To address this potential problem, the government samples edible 
tissues, such as muscle, to monitor for residues.  Due to loss of valuable product and 
analytical difficulties only a small percentage of poultry carcasses are tested.  
Alternatively, antibiotic residue concentrations could be screened in blood, which is 
readily available during poultry carcass processing.  To determine if blood 
concentrations are predictive of muscle concentrations, we conducted two different 
experiments to analyze the efficiency of a blood: tissue relationship in the estimation 
of residue concentration in edible tissues.   
In the first experiment, we evaluated the blood:muscle relationship of the 
enrofloxacin (a fluoroquinolone type antibiotic) in broiler chickens.  Enrofloxacin 
residues were determined in all blood and tissue samples during the dosing period and 
most of the withdrawal period for the two doses used (25 ppm and 50 ppm of 
enrofloxacin in drinking water).  We observed that the tissue: blood correlation for 
fluoroquinolone residues between chicken muscle and blood was approximately 2:1 
for both doses of enrofloxacin.  In other words, the concentration determined in blood 
could be multiplied by two to estimate the concentration present in muscle.  The use 
of blood samples could be an effective tool in the monitoring of antibiotics banned 
from use in poultry (such as enrofloxacin). 
In the second experiment, we evaluated the blood:muscle relationship of the 
antibiotic oxytetracycline in broiler chickens.  Results indicated that blood samples 
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may be used to predict oxytetracycline concentrations in muscle by multiplying blood 
concentrations by a coefficient of 1.3, as a screening procedure for monitoring 
oxytetracycline residues in broiler tissues. 
The use of blood samples as a potential initial screening method to detect 
potentially harmful concentrations of antibiotic residues in poultry muscle could 
provide reliable estimations of the concentration of different antibiotic residues in 
edible tissues (as indicated for monitoring in the Code of Federal Regulations) 
without the need for tissue collection and destruction.  However, even though blood 
residue concentrations were predictive of muscle concentrations for the two 
antibiotics evaluated in this work: enrofloxacin and oxytetracycline, the blood: 
muscle relationship should be determined for other antibiotics of interest to determine 
the utility of blood to estimate potentially harmful concentrations of antibiotic 
residues in poultry edible tissues.  
 
